DGAP-Adhoc: STADA in exclusive negotiations on the purchase of the British OTC manufacturer Thornton & Ross

DGAP-Adhoc: STADA in exclusive negotiations on the purchase of the British OTC 
manufacturer Thornton & Ross

STADA Arzneimittel AG  / Key word(s): Miscellaneous

06.08.2013 10:38

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Bad Vilbel, August 6, 2013 - STADA Arzneimittel AG and the owners of
Thornton & Ross Ltd. have today agreed to negotiate exclusively on the
purchase of the British OTC manufacturer.

Based in Huddersfield, Thornton & Ross was founded in 1922 and has a number
of well-known prescription-free (OTC) branded products for a wide variety
of indications - among other things, cold, pain and dermatology. In
financial year 2012/2013 (April 1, 2012 - March 31, 2013), Thornton & Ross
generated sales of GBP 66.233 million (at the current exchange rate
approximately Euro 76.66 million) and thereby approximately 11 percent more
than in the previous year - for the most part through the pharmacy and
drugstore distribution channels in the United Kingdom. The EBITDA margin in
2012/2013 was above the average for the STADA Group. Thornton & Ross is
currently one of the fastest-growing companies in the British
pharmaceutical market and at the same time number 5 in the British OTC
market. Thornton & Ross has an EU-GMP-certified production site and
currently employs approximately 425 people.

The contract signing and completion of the acquisition are planned for the
third quarter of the current financial year. Consolidation of sales is
sought from September 2013. Payment of the purchase price will be made at
the time of completion. STADA will use cash on hand and existing free
credit lines to finance the acquisition. It is expected that the
transaction will contribute to net income from the time of consolidation.

With a successful acquisition, the STADA Group will strengthen its
business activities in the British pharmaceutical market in the segment for
branded products for self-medication, which is especially strategically
important. In addition, the acquisition provides STADA with the opportunity
to also introduce prescription-free branded products from the comprehensive
Group portfolio in the British market in the future.

Additional information: 
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / 61118
Bad Vilbel - Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101
603-506 / E-mail: communications@stada.de
Or visit us in the Internet at www.stada.com.

06.08.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:     English
Company:      STADA Arzneimittel AG
              Stadastraße 2-18
              61118 Bad Vilbel
Phone:        +49 (0)6101 603- 113
Fax:          +49 (0)6101 603- 506
E-mail:       communications@stada.de
Internet:     www.stada.de
ISIN:         DE0007251803, DE0007251845, 
WKN:          725180, 725184, 
Indices:      MDAX
Listed:       Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
              Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart
End of Announcement                             DGAP News-Service
Press spacebar to pause and continue. Press esc to stop.